BioInItaly Newsletter è la vetrina del biotech italiano all’estero.
Periodicamente offre agli stakeholders internazionali, in lingua inglese, informazioni su quanto accade nel mondo delle biotecnologie italiane.
BioInItaly 4 May 15, 2013
On May 7th, in Milan, it was presented the "Italian Biotechnology Report 2013" by Assobiotec and Ernst & Young in collaboration with Farmindustria and the Italian Trade Promotion Agency, which analyzes industry data in its various areas of application and its performance.
The biotech sector in Italy is a growing and promising reality: the biotech industry is composed of 407 companies, mostly small, employing less than 50 employees. With 235 companies operating in the health-care field, the “Red Biotech” is the prevalent sector.
Total turnover equals € 7,152 million, with a 6% increase compared to the previous year
EryDel SpA (www.erydel.com), a Drug Delivery Company specialized in the development of drugs and diagnostics delivered through red blood cells (RBCs), announced that it has received approval to start its first study in the US. The Investigational New Drug (IND) Application for EryDex (dexamethasone delivered through autologous erythrocytes) was filed on March 24, 2013.
EryDex is an innovative treatment for Ataxia Telangiectasia (AT), a rare autosomal recessive neurological disorder with high mortality. No treatment has been approved for the treatment of the neurological symptoms of AT.
Nicox S.A. (NYSE Euronext Paris: COX) recently announced promising pre-clinical results on naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate, in models of muscular dystrophies. The data were presented by Nicox and the Center for Genetic Medicine Research, a center within the Children's Research Institute, Children's National Medical Center, in a poster session on April 22nd at the Muscular Dystrophy Association (MDA) Scientific Conference in Washington, DC.
The research study data were presented in a poster entitled "Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in mdx mouse model of dystrophy"
Registrazione Tribunale di Milano n. 226 del 4/4/2006
Direttore responsabile Claudio Benedetti